CannabCo Pharmaceutical Corp. has launched its campaign on the Investing News Network’s cannabis channel.

CannabCo is a Canadian-based full-service cannabis company with operations in Brampton, Ontario. The company’s business plan involves the on-going production and supply of pharmaceutical-grade cannabis to both the medical and recreational markets in Canada and internationally. The company intends to distribute its products through pharmaceutical companies, among others. CannabCo is currently waiting to gain approval from Health Canada to become a licensed producer and is building out its pilot facility in the Brampton area.


The pilot facility is expected to employ the most advanced cultivation, processing and packaging technologies with a focus on quality at reduced costs. One such technology CannabCo intends to deploy is PHOENIX, an enhanced cultivation technology that achieves high productivity and significantly lower costs at under C$0.50 per gram. Once the pilot facility is complete and built to EU-GMP standards, the company intends to launch extraction services and enter the oils extracts and consumables markets.

CannabCo’s company highlights include the following:

  • PHOENIX technology that can consistently produce pharmaceutical-grade cannabis at costs of under $.50 per gram indoors.
  • 17,500-square-foot pilot facility is underway expected to produce 5,000 kilograms of cannabis annually.
  • The expansion cultivation facility is expected to produce over 165,000 kilograms per annum.
  • The company is at confirmation of readiness with Health Canada.

Click here to see the educational profile for CannabCo and to request an investor presentation. 

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less